{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:10:46Z","timestamp":1774278646179,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1245\/s10434-020-09137-7","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T23:06:38Z","timestamp":1600556798000},"page":"2913-2922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node?"],"prefix":"10.1245","volume":"28","author":[{"given":"Hayley","family":"Standage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa R.","family":"Hersh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Caughey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Vetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,19]]},"reference":[{"key":"9137_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","volume":"17","author":"DG Coit","year":"2019","unstructured":"Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019. JNCCN J Natl Comp Cancer Netw. 2019;17:367\u2013402. https:\/\/doi.org\/10.6004\/jnccn.2019.0018.","journal-title":"JNCCN J Natl Comp Cancer Netw"},{"key":"9137_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/JCO.2017.75.7724","volume":"36","author":"SL Wong","year":"2018","unstructured":"Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. J Clin Oncol. 2018;36:399\u2013413. https:\/\/doi.org\/10.1200\/jco.2017.75.7724.","journal-title":"J Clin Oncol"},{"key":"9137_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599\u2013609. https:\/\/doi.org\/10.1056\/nejmoa1310460.","journal-title":"N Engl J Med"},{"key":"9137_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/978-3-319-40618-3_47","volume-title":"AJCC cancer staging manual","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scoyler RA, Hess KR, Thompson JF, Long GV, Ross MI, et al. Melanoma of the skin. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC cancer staging manual. Cham: Springer International Publishing; 2017. p. 563\u201385."},{"key":"9137_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1245\/ASO.2006.03.058","volume":"13","author":"SL Wong","year":"2006","unstructured":"Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol. 2006;13:809\u201316. https:\/\/doi.org\/10.1245\/aso.2006.03.058.","journal-title":"Ann Surg Oncol"},{"key":"9137_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/jso.25444","volume":"119","author":"ND Klemen","year":"2019","unstructured":"Klemen ND, Han G, Leong SP, et al. Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. J Surg Oncol. 2019;119:1053\u20139. https:\/\/doi.org\/10.1002\/jso.25444.","journal-title":"J Surg Oncol"},{"key":"9137_CR7","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"B Faries","year":"2017","unstructured":"Faries B, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211\u201322. https:\/\/doi.org\/10.1056\/nejmoa1613210.","journal-title":"N Engl J Med"},{"key":"9137_CR8","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.18.02306","volume":"37","author":"U Leiter","year":"2019","unstructured":"Leiter U, Stadler R, Mauch C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37:3000\u20138. https:\/\/doi.org\/10.1200\/jco.18.02306.","journal-title":"J Clin Oncol."},{"key":"9137_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy-positive melanoma (DeCOG-SLT): a multicentre, randomized, phase 3 trial. Lancet Oncol. 2016;17:757\u201367. https:\/\/doi.org\/10.1016\/s1470-2045(16)00141-8.","journal-title":"Lancet Oncol."},{"key":"9137_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801. https:\/\/doi.org\/10.1056\/nejmoa1802357.","journal-title":"N Engl J Med"},{"key":"9137_CR11","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335. https:\/\/doi.org\/10.1056\/nejmoa1709030.","journal-title":"N Engl J Med"},{"key":"9137_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323. https:\/\/doi.org\/10.1056\/nejmoa1708539.","journal-title":"N Engl J Med"},{"key":"9137_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0442-7","volume":"6","author":"V Verma","year":"2018","unstructured":"Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. J Immunother Cancer. 2018;6:1\u201315. https:\/\/doi.org\/10.1186\/s40425-018-0442-7.","journal-title":"J Immunother Cancer"},{"key":"9137_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40261-018-0690-9","volume":"38","author":"FS Mennini","year":"2018","unstructured":"Mennini FS, Bini C, Marcellusi A, del Vecchio M. Cost estimate of immune-related adverse reactions associated with innovative treatments of metastatic melanoma. Clin Drug Investig. 2018;38:967\u201376. https:\/\/doi.org\/10.1007\/s40261-018-0690-9.","journal-title":"Clin Drug Investig"},{"key":"9137_CR15","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1245\/s10434-019-07369-w","volume":"26","author":"DC Thomas","year":"2019","unstructured":"Thomas DC, Han G, Leong SP, et al. Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on survival. Ann Surg Oncol. 2019;26:2254\u201362. https:\/\/doi.org\/10.1245\/s10434-019-07369-w.","journal-title":"Ann Surg Oncol"},{"key":"9137_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz011.","journal-title":"Ann Oncol"},{"key":"9137_CR17","doi-asserted-by":"publisher","first-page":"505302","DOI":"10.1155\/2015\/505302","volume":"2015","author":"V Shih","year":"2015","unstructured":"Shih V, ten Ham RM, Bui CT, Tran DN, Ting J, Wilson L. Targeted therapies compared to dacarbazine for treatment of BRAF(V600E) metastatic melanoma: a cost-effectiveness analysis. J Skin Cancer. 2015;2015:505302. https:\/\/doi.org\/10.1155\/2015\/505302.","journal-title":"J Skin Cancer"},{"key":"9137_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.18553\/jmcp.2017.23.6.653","volume":"23","author":"A Oh","year":"2017","unstructured":"Oh A, Tran DM, McDowell LC, et al. Cost-effectiveness of nivolumab\u2013ipilimumab combination therapy compared with monotherapy for first-line treatment of metastatic melanoma in the United States. J Manag Care Spec Pharm. 2017;23:653\u201364. https:\/\/doi.org\/10.18553\/jmcp.2017.23.6.653.","journal-title":"J Manag Care Spec Pharm"},{"key":"9137_CR19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093\u2013103. https:\/\/doi.org\/10.1001\/jama.2016.12195.","journal-title":"JAMA"},{"key":"9137_CR20","unstructured":"Consumer Price Index: Medical Component. Bureau of Labor Statistics. Published 2019. https:\/\/www.bls.gov\/cpi\/home.htm. Accessed 5 Jan 2019."},{"key":"9137_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/jso.23833","volume":"111","author":"NJL Hong","year":"2015","unstructured":"Hong NJL, Petrella T, Chan K. Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma. J Surg Oncol. 2015;111:423\u201330. https:\/\/doi.org\/10.1002\/jso.23833.","journal-title":"J Surg Oncol"},{"key":"9137_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.18553\/jmcp.2017.23.2.184","volume":"23","author":"J Wang","year":"2017","unstructured":"Wang J, Chmielowski B, Pellissier J, Xu R, Stevinson K, Liu FX. Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-na\u00efve patients with advanced melanoma in the United States. J Manag Care Spec Pharm. 2017;23:184\u201394. https:\/\/doi.org\/10.18553\/jmcp.2017.23.2.184.","journal-title":"J Manag Care Spec Pharm"},{"key":"9137_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1245\/s10434-008-0164-z","volume":"16","author":"RL Morton","year":"2009","unstructured":"Morton RL, Howard K, Thompson JF. The cost-effectiveness of sentinel node biopsy in patients with intermediate thickness primary cutaneous melanoma. Ann Surg Oncol. 2009;16:929\u201340. https:\/\/doi.org\/10.1245\/s10434-008-0164-z.","journal-title":"Ann Surg Oncol"},{"key":"9137_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-014-0140-1","volume":"12","author":"AJ Hatswell","year":"2014","unstructured":"Hatswell AJ, Pennington B, Pericleous L, Rowen D, Lebmeier M, Lee D. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcomes. 2014;12:1\u20139. https:\/\/doi.org\/10.1186\/s12955-014-0140-1.","journal-title":"Health Qual Life Outcomes"},{"key":"9137_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","volume":"86","author":"O Hamid","year":"2017","unstructured":"Hamid O, Puzanov I, Dummer R, et al. Final analysis of a randomized trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017;86:37\u201345. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.022.","journal-title":"Eur J Cancer"},{"key":"9137_CR26","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332. https:\/\/doi.org\/10.1056\/nejmoa1503093.","journal-title":"N Engl J Med"},{"key":"9137_CR27","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600\u20139. https:\/\/doi.org\/10.1001\/jama.2016.4059.","journal-title":"JAMA"},{"key":"9137_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","volume":"67","author":"D Schadendorf","year":"2016","unstructured":"Schadendorf D, Dummer R, Hauschild A, et al. Health-related quality of life in the randomized KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016;67:46\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2016.07.018.","journal-title":"Eur J Cancer"},{"key":"9137_CR29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/13696998.2019.1609485","volume":"22","author":"AG Bensimon","year":"2019","unstructured":"Bensimon AG, Zhou ZY, Jenkins M, et al. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. J Med Econ. 2019;22:981\u201393. https:\/\/doi.org\/10.1080\/13696998.2019.1609485.","journal-title":"J Med Econ"},{"key":"9137_CR30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jval.2017.05.009","volume":"20","author":"LS Miguel","year":"2017","unstructured":"Miguel LS, Lopes FV, Pinheiro B, et al. Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal. Value Health. 2017;20:1065\u201373. https:\/\/doi.org\/10.1016\/j.jval.2017.05.009.","journal-title":"Value Health"},{"key":"9137_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s12325-016-0283-z","volume":"33","author":"Q Ma","year":"2016","unstructured":"Ma Q, Zhao Z, Barber BL, Shilkrut M. Use patterns and costs of isolated limb perfusion and infusion in the treatment of regional metastatic melanoma: a retrospective database analysis. Adv Ther. 2016;33:282\u20139. https:\/\/doi.org\/10.1007\/s12325-016-0283-z.","journal-title":"Adv Ther"},{"key":"9137_CR32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/s0039-6060(03)00275-7","volume":"134","author":"DM Agnese","year":"2003","unstructured":"Agnese DM, Abdessalam SF, Burak WE Jr, Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134:542\u20138. https:\/\/doi.org\/10.1016\/s0039-6060(03)00275-7.","journal-title":"Surgery"},{"key":"9137_CR33","doi-asserted-by":"publisher","first-page":"212297","DOI":"10.7573\/dic.2122","volume":"5","author":"IS Jensen","year":"2016","unstructured":"Jensen IS, Zacherle E, Blanchette CM, Zhang J, Yin W. Evaluating cost benefits of combination therapies for advanced melanoma. Drugs Context. 2016;5:212297. https:\/\/doi.org\/10.7573\/dic.2122.","journal-title":"Drugs Context."},{"key":"9137_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/archderm.143.1.21","volume":"143","author":"E Losina","year":"2007","unstructured":"Losina E, Walensky RP, Geller A, et al. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol. 2007;143:21\u20138. https:\/\/doi.org\/10.1001\/archderm.143.1.21.","journal-title":"Arch Dermatol"},{"key":"9137_CR35","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1245\/s10434-010-0919-1","volume":"17","author":"JC Boughey","year":"2010","unstructured":"Boughey JC, Moriarty JP, Degnim AC, Gregg MS, Egginton JS, Long KH. Cost modeling of preoperative axillary ultrasound and fine-needle aspiration to guide surgery for invasive breast cancer. Ann Surg Oncol. 2010;17:953\u20138. https:\/\/doi.org\/10.1245\/s10434-010-0919-1.","journal-title":"Ann Surg Oncol"},{"key":"9137_CR36","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1002\/cncr.25068","volume":"116","author":"AL Cheville","year":"2010","unstructured":"Cheville AL, Almoza M, Courmier JN, Basford JR. A prospective cohort study defining utilities using time trade-offs and the euroqol-5D to assess the impact of cancer-related lymphedema. Cancer. 2010;116:3722\u201331. https:\/\/doi.org\/10.1002\/cncr.25068.","journal-title":"Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09137-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09137-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09137-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:10:32Z","timestamp":1632010232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09137-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,19]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["9137"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09137-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,19]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Taylor is a consulting\/advisory board member for Bristol Myers Squibb, Eisai Inc, Loxo Oncology, Bayer, Novartis, Genzyme\/Sanofi, Array Biopharma and serves on the speaker\u2019s bureau for Bristol Myers Squibb, Eisai Inc, and Merck. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}